💼 Goldman Sachs (GS): One Year Later—When a Great Investment Becomes a Great Company
Last year, insider buying and an attractive valuation made Goldman Sachs one of our favorite ideas. The stock has since more than doubled. Here's why the business remains exceptional—but the investment opportunity has fundamentally changed.
🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued
Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.
🦸♂️ The Attic of the Soul: Why Your $9M “Super Moment” Is Covered in Dust
A dusty attic revealed a $9.1M treasure. Most of us have something similar—buried ideas, talents, or ambitions waiting to be rediscovered. The question is: will you climb the ladder?
S&P 500 PE Ratio Hits 30: Is a 2026 Bear Market Black Swan Immersion Imminent?
With the S&P 500 trading at nearly twice its historical P/E average, valuations are stretched. Even a 20% drop wouldn’t make stocks cheap. Is 2026 the year gravity reasserts itself?
No Bullish Trigger: Ginkgo Bioworks Should Read “Ginkgo Bio… Doesn’t Work”
Ginkgo Bioworks (DNA) has ambitious science and flashy AI rhetoric — but declining revenues, deep losses, and no insider conviction make this a tough stock to love. 🧬📉
Could Darling Become One? Shares Jump on an Ingredients-Fueled Beat
From fryer oil to future fuel: DAR beat on sales, guided core EBITDA to $875–900M, and is monetizing PTCs while prepping SAF scale-up. Fun + smart breakdown with TL;DR & FAQs.
Funds and Analysts Love BioMarin Pharmaceutical (BMRN), A Rare Combo of Value and Growth Fighting Also Rare Genetic Diseases. Should You?
BioMarin is that rare biotech: profits, pipeline, and price discipline. VOXZOGO grows, margins expand, and catalysts stack—at a surprisingly modest valuation.
Year-Old CEO Could Start Making an Impact: Can Teladoc (TDOC) Reboot Growth, Turn a Profit, and Send Its Stock Back to the Moon?
Teladoc Health is down 97% from ATH — but Citron says Livongo is booming, institutions are buying, and the CEO just hit his one-year mark. Bargain bin or value trap?
Target: Can the New CEO Finally Attract Bull’s Eye?
Target stock has lost 2/3 of its value since 2021. With a new CEO, strong dividends, and institutional support, is this retailer ready to bounce back?
Duolingo (DUOL): A Compelling Growth Investment and A Buy in Any Language?
Duolingo (DUOL) is flying high with 41% revenue growth, record profits, and a chess course attracting millions. Institutions can’t get enough. But is the stock a smart buy—or just owl-wardly expensive?